Home Newsfeeds UK Conservative Chief Whip Wendy Morton Resigns

UK Conservative Chief Whip Wendy Morton Resigns

– Bloomberg

byBenzinga Newsdesk

October 19, 2022

1 minute read

– Bloomberg

Freeline Therapeutics Announces Second Round Of Layoffs, Shelves Fabry Disease Program

By Vandana Singh

April 4, 1:41 PM

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) further assessed its strategic priorities and decided to pause the development of FLT190 in Fabry disease…

FRLN

News

Dorman Launches 400+ New Motor Vehicle Repair Solutions, Rapidly Expanding Coverage For SUVs, EVs And Heavy-Duty Trucks

By Benzinga Newsdesk

October 14, 10:27 AM

Dorman Products, Inc. (NASDAQ:DORM) is announcing the release of more than 400 new motor vehicle parts, almost half of which are first-to-the-aftermarket exclusives. The new products join a growing catalog of 118,000+

DORM

Reported Late Wednesday, WuXi Biologics And GSK Enter Into License Agreement On Multiple Novel Bi- & Multi-specific T Cell Engagers; Wuxi Biologics Will Receive An Upfront Payment Of $40M And Tiered Royalties On Net Sales

By Benzinga Newsdesk

January 5, 1:36 AM

WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi

GSK

Everbridge Q2 EPS $0.03, Same YoY, Sales $103.00M Beat $102.02M Estimate

By Benzinga Newsdesk

August 9, 4:26 PM

Everbridge (NASDAQ:EVBG) reported quarterly earnings of $0.03 per share. This is unchanged from the same period last year. The company reported quarterly sales of $103.00 million which beat the analyst consensus

EVBG

UK Conservative Chief Whip Wendy Morton Resigns

Related Posts

Freeline Therapeutics Announces Second Round Of Layoffs, Shelves Fabry Disease Program

Dorman Launches 400+ New Motor Vehicle Repair Solutions, Rapidly Expanding Coverage For SUVs, EVs And Heavy-Duty Trucks

Reported Late Wednesday, WuXi Biologics And GSK Enter Into License Agreement On Multiple Novel Bi- & Multi-specific T Cell Engagers; Wuxi Biologics Will Receive An Upfront Payment Of $40M And Tiered Royalties On Net Sales

Everbridge Q2 EPS $0.03, Same YoY, Sales $103.00M Beat $102.02M Estimate